KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $21.39 $29.07 Thursday, 25th Apr 2024 ARWR stock ended at $21.87. This is 6.10% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 7.06% from a day low at $21.39 to a day high of $22.90.
90 days $21.39 $36.72
52 weeks $20.67 $42.48

Historical Arrowhead Research Corporation prices

Date Open High Low Close Volume
Jan 08, 2024 $35.10 $39.53 $34.37 $39.48 5 163 886
Jan 05, 2024 $33.89 $35.99 $33.32 $35.60 2 840 723
Jan 04, 2024 $32.63 $34.80 $32.59 $34.53 4 870 028
Jan 03, 2024 $32.65 $34.31 $31.16 $31.97 5 984 885
Jan 02, 2024 $30.50 $32.15 $29.65 $31.01 764 917
Dec 29, 2023 $31.22 $31.68 $30.55 $30.60 810 091
Dec 28, 2023 $30.88 $31.57 $30.52 $31.00 888 337
Dec 27, 2023 $31.05 $31.55 $30.53 $31.03 650 988
Dec 26, 2023 $30.68 $31.16 $30.10 $30.89 671 390
Dec 22, 2023 $29.00 $30.44 $29.00 $30.35 929 191
Dec 21, 2023 $28.33 $28.90 $28.12 $28.76 976 612
Dec 20, 2023 $29.90 $30.00 $27.77 $27.83 1 085 795
Dec 19, 2023 $28.38 $30.09 $28.36 $30.00 1 458 540
Dec 18, 2023 $28.59 $28.93 $27.34 $27.94 868 685
Dec 15, 2023 $28.64 $29.48 $27.73 $28.55 2 716 028
Dec 14, 2023 $27.53 $29.28 $27.53 $28.55 1 615 765
Dec 13, 2023 $24.63 $26.91 $24.55 $26.90 1 597 052
Dec 12, 2023 $23.79 $24.79 $23.06 $24.69 940 920
Dec 11, 2023 $24.37 $24.50 $23.70 $23.87 1 108 925
Dec 08, 2023 $24.44 $25.10 $23.92 $23.95 912 424
Dec 07, 2023 $23.79 $24.93 $23.52 $24.53 1 229 886
Dec 06, 2023 $23.70 $23.92 $23.36 $23.79 1 431 839
Dec 05, 2023 $24.56 $24.73 $23.40 $23.43 1 443 232
Dec 04, 2023 $23.33 $24.93 $23.20 $24.93 2 794 927
Dec 01, 2023 $21.55 $23.24 $20.67 $23.17 4 217 172
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT